Hepatitis B Vaccination in HIV-Infected Youth: A Randomized Trial of Three Regimens

被引:41
|
作者
Flynn, Patricia M. [1 ,2 ,3 ]
Cunningham, Coleen K. [4 ]
Rudy, Bret [5 ]
Wilson, Craig M. [6 ]
Kapogiannis, Bill [7 ]
Worrell, Carol [7 ]
Bethel, James [8 ]
Monte, Dina [8 ]
Bojan, Kelly [9 ]
机构
[1] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA
[2] Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Memphis, TN USA
[3] Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Memphis, TN USA
[4] Duke Univ, Dept Pediat, Sch Med, Durham, NC 27706 USA
[5] NYU, Dept Pediat, Sch Med, New York, NY 10016 USA
[6] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA
[7] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Adolescent & Maternal AIDS Branch, NIH, Rockville, MD USA
[8] Westat Corp, Rockville, MD USA
[9] Core Ctr, Adolescent Div, Chicago, IL USA
基金
美国国家卫生研究院;
关键词
HIV; hepatitis B vaccination; adolescents; Engerix B; Twinrix; IMPAIRED RESPONSE; SEROLOGIC RESPONSE; ANTIBODY-RESPONSE; HOMOSEXUAL MEN; A VACCINE; CHILDREN; IMMUNIZATION; EFFICACY; INFANTS; IMMUNOGENICITY;
D O I
10.1097/QAI.0b013e318203e9f2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: HIV-infected youth are at risk of hepatitis B infection and should be vaccinated. Previous reports suggest reduced response to standard hepatitis B vaccine regimens. Methods: HIV-infected youth, aged 12 to younger than 25 years, were randomly assigned to one of three treatment arms: Arm 1: Engerix B, 20 mg HBsAg; Arm 2: Engerix B (GlaxoSmithKline, Rixensart, Belgium), 40 mg; and Arm 3: Twinrix (GlaxoSmithKline, Rixensart, Belgium), 20 mg HBsAg combined with 720 ELU hepatitis A antigen. Vaccines were administered at Weeks 0, 4, and 24. Results: Characteristics of evaluable patients (n = 336) at entry were similar in the study arms. At enrollment, median CD4(+) T-cell count was 460 cells/mm(3) (interquartile range, 305-668); 13% were less than 200 cells/mm(3). Among Engerix B, 20-mg recipients, 60.4% responded to vaccine (HBsAb 10 IU/mL or greater at Week 28). Improved vaccine response was seen in recipients of Engerix B, 40 mg (73.2% versus Arm 1, P = 0.04) and Twinrix (75.4% versus Arm 1, P = 0.02). In multivariate analysis, only baseline CD4(+) T-cell count and study arm were independent predictors of vaccine response. Conclusions: In HIV-infected youth, a three-dose vaccination regimen with Engerix B, 40 mg, or Twinrix and higher baseline CD4(+) T-cell counts were independently associated with improved vaccine response.
引用
收藏
页码:325 / 332
页数:8
相关论文
共 50 条
  • [1] Randomized trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy
    Rivero, A
    López-Cortés, L
    Castillo, R
    Lozano, F
    García, MA
    Díez, F
    Escribano, JC
    Canueto, J
    Pasquau, J
    Hernández, JJ
    Polo, R
    Martínez-Marcos, FJ
    Kindelán, JM
    Rey, R
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2003, 21 (06): : 287 - 292
  • [2] Hepatitis B Vaccination Strategy in HIV-infected Children
    Dewan, Pooja
    Gupta, Piyush
    INDIAN PEDIATRICS, 2017, 54 (12) : 1001 - 1003
  • [3] Hepatitis B and A vaccination in HIV-infected adults: A review
    Mena, G.
    Garcia-Basteiro, A. L.
    Bayas, J. M.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (11) : 2582 - 2598
  • [4] Hepatitis B vaccination strategy in HIV-infected children
    Pooja Dewan
    Piyush Gupta
    Indian Pediatrics, 2017, 54 : 1001 - 1004
  • [5] Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals
    Landrum, Michael L.
    Hullsiek, Katherine Huppler
    Ganesan, Anuradha
    Weintrob, Amy C.
    Crum-Cianflone, Nancy F.
    Barthel, R. Vincent
    O'Connell, Robert J.
    Fieberg, Ann
    Chun, Helen M.
    Marconi, Vincent C.
    Dolan, Matthew J.
    Agan, Brian K.
    AIDS, 2010, 24 (04) : 545 - 555
  • [6] Mindfulness instruction for HIV-infected youth: a randomized controlled trial
    Webb, Lindsey
    Perry-Parrish, Carisa
    Ellen, Jonathan
    Sibinga, Erica
    AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2018, 30 (06): : 688 - 695
  • [7] Hepatitis B virus vaccination in HIV-infected people: A review
    Catherine, Francois-Xavier
    Piroth, Lionel
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (06) : 1304 - 1313
  • [8] Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients
    Rivero, Antonio
    Lopez-Cortes, Luis
    Castillo, Rafael
    Verdejo, Jose
    Angel Garcia, Miguel
    Martinez-Marcos, Francisco Javier
    Diez, Felipe
    Carlos Escribano, Jose
    Canueto, Jesus
    Lozano, Fernando
    Pasquau, Juan
    Jose Hernandez, Juan
    Marquez, Manuel
    Maria Kindelan, Jose
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2007, 25 (05): : 305 - 310
  • [9] Response to hepatitis B vaccination among HIV-infected adults in Vietnam
    Pollack, Todd M.
    Le Thi Thu Trang
    Long Ngo
    Do Duy Cuong
    Pham Thanh Thuy
    Colby, Donn J.
    JOURNAL OF VIRUS ERADICATION, 2016, 2 (02) : 102 - 106
  • [10] Hepatitis B vaccination is effective among HIV-infected adults in Uganda
    Seremba, Emmanuel
    Ocama, Ponsiano
    Ssekitoleko, Richard
    Mayanja-Kizza, Harriet
    Katabira, Elly
    Reynolds, Steven J.
    Nabatanzi, Rose
    Casper, Corey
    Phipps, Warren
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E267 - E267